Clinical Trials
98
10 active
Approvals
10
Total approvals
Agencies
1
Regulatory bodies
Founded
N/A
Active, not recruiting
1
1.0%
Completed
64
65.3%
Enrolling By Invitation
1
1.0%
Not yet recruiting
8
8.2%
Recruiting
5
5.1%
Unknown
18
18.4%
Withdrawn
1
1.0%
- DelveInsight's 2025 pipeline analysis reveals over 10 companies developing 12+ therapies for gastroesophageal reflux disease, with novel potassium-competitive acid blockers leading innovation. - Onconic Therapeutics' Zastaprazan has entered Phase III trials for reflux esophagitis, representing a new P-CAB class that offers longer duration of action compared to traditional proton pump inhibitors. - Cinclus Pharma's X842, a prodrug of linaprazan, is advancing through Phase II development with potential to heal esophageal injuries more effectively than current pharmaceutical therapies. - The GERD market addresses a significant unmet need, with the condition affecting 20% of the US population and creating substantial economic burden through direct and indirect costs.
- Dr. Reddy's Laboratories has launched tegoprazan, a next-generation potassium-competitive acid blocker (PCAB), in India for treating acid peptic diseases including GERD and gastric ulcers. - The drug offers rapid onset of action and sustained gastric pH control, potentially providing significant clinical benefits over existing therapies in acid peptic disease management. - Tegoprazan is already approved in 21 countries including South Korea and China, and has successfully completed Phase III trials in the United States. - The launch follows Dr. Reddy's exclusive 2022 partnership with South Korea-based HK inno.N Corporation to commercialize the molecule in India and select emerging markets.
